On Thursday, BofA Securities maintained their Underperform rating and an $18.00 stock price target for Myriad Genetics (NASDAQ:MYGN). Following Myriad Genetics' Analyst Day, BofA Securities commented on the company's efforts to transform its business. The event highlighted Myriad Genetics' updated portfolio, market strategy, and medium-term guidance through 2026, alongside internal research and development projects.
Despite recognizing the progress Myriad Genetics has made in transforming its business model, BofA Securities expressed caution regarding the company's financial targets. The firm noted a lack of clear, near-term catalysts that could significantly elevate the company's stock value.
During the Analyst Day, Myriad Genetics presented an in-depth overview of its revamped product lineup and commercial strategy. The company also discussed its position within the market landscape and provided updates on its medium-term guidance, projecting through the year 2026.
BofA Securities highlighted the internal research and development efforts at Myriad Genetics as part of the company's transformation. These projects are integral to the company's strategy for growth and market adaptation.
In conclusion, while acknowledging the positive steps Myriad Genetics is taking, BofA Securities remains conservative with their outlook on the company's stock. The maintained Underperform rating and $18.00 price target reflect the firm's view that more significant drivers are needed to boost Myriad Genetics' share performance in the near term.
In other recent news, Myriad Genetics has been making strides in breast cancer molecular residual disease (MRD) testing research through multiple collaborations. The company is working with The University of Texas MD Anderson Cancer Center and The University of Rochester Medical Center to study the predictive power of circulating tumor DNA (ctDNA) levels in various treatment scenarios.
Furthermore, Myriad Genetics is participating in the MONITOR-breast study and the JBCRG-C11 (CREA) study in Japan, both focusing on the prognostic value of ctDNA levels in breast cancer management.
Myriad Genetics recently reported second-quarter revenues of $211.5 million, exceeding consensus expectations, and consequently raised its 2024 guidance to an estimated $835-845 million. Analyst firms including Wolfe Research, Scotiabank, Jefferies, and TD Cowen reacted positively to these developments, raising their price targets for the company.
In other company news, Myriad Genetics discontinued part of its GeneSight study due to disparities in baseline hospital resource utilization and costs between the tested and control groups. Wells Fargo listed Myriad Genetics among its high-conviction ideas for sustained growth into 2025. These recent developments reflect the ongoing momentum of Myriad Genetics in the genetic testing and precision medicine field.
InvestingPro Insights
Recent InvestingPro data provides additional context to Myriad Genetics' (NASDAQ:MYGN) current financial position and market performance. Despite BofA Securities' cautious outlook, the company has shown a strong revenue growth of 14.78% over the last twelve months, with Q2 2024 revenue reaching $802.2 million. This growth aligns with Myriad's efforts to transform its business model, as discussed during their Analyst Day.
InvestingPro Tips highlight that 6 analysts have revised their earnings upwards for the upcoming period, suggesting some optimism about Myriad's near-term performance. This contrasts with BofA's view on the lack of clear catalysts. Moreover, the stock has demonstrated a high return over the last year, with a 1-year price total return of 59.07%, indicating investor confidence in the company's transformation efforts.
However, it is important to note that Myriad Genetics is currently not profitable, with a negative operating income of $103.3 million over the last twelve months. This aligns with BofA's caution regarding the company's financial targets.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for Myriad Genetics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.